MariMed Inc.

MariMed earns a Neutral rating with a 47.8 composite score and low 1/5 conviction. Fundamentals lead at 60.0, supported by the strongest underlying contributions from EBITDA-positive cash generation, a 0.75% operating margin, and a gross margin approaching 36%. Regulatory follows at 49.0, reflecting a balanced jurisdiction posture and no enforcement hits, offset by weak filing cadence. Market ranks at 40.0 because institutional pricing feeds provide no current quote, limiting price-based confirmation. Editorial trails at 30.0, consistent with no newsroom or brief activity in CIN newsroom coverage. The pillar mix supports a middle-band rating rather than a directional call.

Licensed fundamentals data show year-over-year revenue growth of 4.2%, positive but insufficient to create a broad growth premium. Gross profitability remains the central operating support, while the narrow operating margin indicates limited room for execution slippage. EBITDA stands near $10.6 million, yet the approximately $12.8 million net loss preserves the stretched financial condition; positive EBITDA does not erase bottom-line pressure. The roughly $27.2 million market capitalization also constrains the fundamentals score despite stronger operating and cash-runway subscores. Primary regulatory filings show no tracked events over either the past 90 days or 180 days and no enforcement hits, but the absence of a latest filing date weakens cadence visibility. Institutional pricing feeds provide no available quote, while CIN newsroom coverage records no qualifying news or brief hits.

The forward case rests on fundamentals, the highest-scoring pillar and the clearest route to a stronger composite. Continued revenue expansion combined with gross-margin stability could create operating leverage from the current slim operating base, enabling EBITDA strength to translate more convincingly into bottom-line improvement. That conversion carries greater rating relevance than regulatory, market, or editorial changes because the present Neutral stance is anchored by a profitable operating framework alongside a material net loss and stretched condition. A sustained move from positive EBITDA toward positive net income is the single most important signal to watch.